Live Poll Results — Which pricing strategy became particularly prevalent for rare disease medication
See real-time poll results. Powered by AIPolls.Net.
Pharmaceutical Pricing Puzzler: The Orphan Drug Act Effect
The pharmaceutical industry employs various pricing strategies, especially for rare disease treatments. The Orphan Drug Act of 1983 created specific incentives that dramatically shaped how certain medications are priced in the market. This poll tests your knowledge of how this landmark legislation affected pharmaceutical pricing strategies for rare disease treatments. Do you understand the economic factors behind some of medicine's most expensive therapies?
Which pricing strategy became particularly prevalent for rare disease medications following the Orphan Drug Act of 1983?
Poll Type: Trivia | Total Votes: 0
| Option | Votes | Percentage |
|---|---|---|
| {'choice_text': 'Value-based pricing with premiums reflecting the high clinical value and limited patient population', 'is_correct': True} | 0 | 0% |
| {'choice_text': 'Cost-plus pricing focused primarily on recouping R&D investments plus standard industry margins', 'is_correct': False} | 0 | 0% |
| {'choice_text': 'Reference pricing aligning with international standards for similar therapeutic categories', 'is_correct': False} | 0 | 0% |
| {'choice_text': 'Loss-leader pricing to build market share before implementing subscription-based payment models', 'is_correct': False} | 0 | 0% |